Our laboratory has developed techniques for directly targeting intracellular oncogene products. Preliminary studies showed that a K- ras antisense (AS-K-ras) expression vector can specifically eliminate expression of K-ras p21.
The specific aims outlined below are designed to study transduction of both AS-K-ras and the tumor suppressor wildtype p53 cDNA (wtp53) with viral vectors. The viral vectors LNSX, N2A, and adeno-associated virus (AAV) will be used to prepare the following constructs: LNSX (S-K-ras, AS-K-ras, p53), N2A- (S-K-ras, AS-K-ras, p53), AAV (S-K-ras, AS-K-ras). The GP+envAM-12 amphotropic packaging cell line will be used for production of infectious retroviral particles. These viral constructs will be used to transduce the following human cancer cell lines: H460a (wtp53 and mut K-ras), H358 (del p53 and wt K-ras), H322a (mut p53 and wtp53). The following parameters will be assessed for each transduced cell line: 1) Growth rate of cells by cell counts and [3H]Thd uptake; 2) Level of expression by mRNA; 3) Differential expression of other related genes such as H-ras and N-ras; 4) Level of protein expression by Western blot; 5) tumorigenicity of cells in nu/nu mice. The efficiency of transduction will be determined by assessment of colony formation in selective media. Changes in efficiency mediated by changes in viral titer and by multiple cycles of infection will be determined. The biodistribution of constructs in non-tumor bearing immunocompetent and nu/nu mice will be assessed. We will study the distribution both short (hrs) and long-term (wks and months). The distribution and expression of the constructs in different tissues will be studied after systemic and regional administration. The long-term effects on the whole animal will be determined. The effect of systemic and regional administration of viral constructs on subcutaneous and endobronchial tumor growth will be determined. Systemic administration of protamine will be evaluated as an adjunct for increasing efficiency of transduction in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA045187-06
Application #
3188216
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1992-07-01
Project End
1995-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Hamada, Katsuyuki; Sakaue, Morito; Sarkar, Asis et al. (2005) Immune responses to repetitive adenovirus-mediated gene transfer and restoration of gene expression by cyclophosphamide or etoposide. Gynecol Oncol 99:S177-86
Hamada, Katsuyuki; Ueda, Norifumi; Ito, Masaharu et al. (2005) The nude rat as an orthotopic model for cervical cancer. Gynecol Oncol 99:S159-65
Yen, N; Ioannides, C G; Xu, K et al. (2000) Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7:530-6
Fukazawa, T; Fujiwara, T; Morimoto, Y et al. (1999) Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene 18:2189-99
Swisher, S G; Roth, J A; Nemunaitis, J et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763-71
Roth, J A; Swisher, S G; Meyn, R E (1999) p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park) 13:148-54
Nishizaki, M; Fujiwara, T; Tanida, T et al. (1999) Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5:1015-23
Roth, J A (1998) Restoration of tumour suppressor gene expression for cancer. Forum (Genova) 8:368-76
Roth, J A; Swisher, S G; Merritt, J A et al. (1998) Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25:33-7
Mukhopadhyay, T; Multani, A S; Roth, J A et al. (1998) Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Oncogene 17:901-6

Showing the most recent 10 out of 77 publications